Literature DB >> 2883199

Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation.

J M Puck, R L Nussbaum, M E Conley.   

Abstract

The X-linked form of severe combined immunodeficiency (XSCID) is underdiagnosed because no methods have been available for detecting carriers. Although boys with XSCID are deficient in T cells, female carriers are immunologically normal. Carriers' normal immune function would be expected if all their T cells were derived from precursors whose X chromosome bearing the XSCID mutation was inactivated early in embryogenesis. Using somatic cell hybridization to separate the active and inactive X chromosomes and restriction fragment length polymorphisms to distinguish them, we have determined the lymphocyte X inactivation pattern in XSCID carriers and their female relatives. In the T cells of three carriers, the X chromosome bearing the XSCID mutation was consistently inactive. Nonrandom X inactivation was also found in the T cells of one at-risk female, while two others had normal, random X inactivation. This method constitutes a generally applicable carrier test for XSCID.

Entities:  

Mesh:

Year:  1987        PMID: 2883199      PMCID: PMC424401          DOI: 10.1172/JCI112967

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Report of the Committee on the Genetic Constitution of the X and Y Chromosomes.

Authors:  P N Goodfellow; K E Davies; H H Ropers
Journal:  Cytogenet Cell Genet       Date:  1985

2.  Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms.

Authors:  P R Winship; D S Anson; C R Rizza; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1984-12-11       Impact factor: 16.971

3.  In vitro regulation of IgA subclass synthesis. II. The source of IgA2 plasma cells.

Authors:  M E Conley; M S Bartelt
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

Review 4.  Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy.

Authors:  R Hirschhorn
Journal:  Birth Defects Orig Artic Ser       Date:  1983

5.  A strategy to reveal high-frequency RFLPs along the human X chromosome.

Authors:  J Aldridge; L Kunkel; G Bruns; U Tantravahi; M Lalande; T Brewster; E Moreau; M Wilson; W Bromley; T Roderick
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

6.  Rapid transfer of DNA from agarose gels to nylon membranes.

Authors:  K C Reed; D A Mann
Journal:  Nucleic Acids Res       Date:  1985-10-25       Impact factor: 16.971

7.  X inactivation patterns in two syndromes with probable X-linked dominant, male lethal inheritance.

Authors:  P Wieacker; J Zimmer; H H Ropers
Journal:  Clin Genet       Date:  1985-09       Impact factor: 4.438

8.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  Two anonymous X-specific human sequences detecting restriction fragment length polymorphisms in region Xq26----qter.

Authors:  B A Boggs; R L Nussbaum
Journal:  Somat Cell Mol Genet       Date:  1984-11

10.  XX T cells and XY B cells in two patients with severe combined immune deficiency.

Authors:  M E Conley; P C Nowell; G Henle; S D Douglas
Journal:  Clin Immunol Immunopathol       Date:  1984-04
View more
  37 in total

Review 1.  Genetics of human X-linked immunodeficiency diseases.

Authors:  R W Hendriks; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  Differential methylation at the 5' and the 3' CCGG sites flanking the X chromosomal hypervariable DXS255 locus.

Authors:  R W Hendriks; M E Kraakman; R G Mensink; R K Schuurman
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

Review 3.  Genetic control of X inactivation and processes leading to X-inactivation skewing.

Authors:  J W Belmont
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 4.  Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.

Authors:  J J O'Shea; L D Notarangelo; J A Johnston; F Candotti
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

5.  Nonrandom X-chromosome inactivation in hemopoietic cells from carriers of dyskeratosis congenita.

Authors:  A M Ferraris; G L Forni; R Mangerini; G F Gaetani
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

6.  Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations.

Authors:  G N Fredrikson; B Gullstrand; J Westberg; A G Sjöholm; M Uhlén; L Truedsson
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

7.  Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females.

Authors:  E Pegoraro; R N Schimke; K Arahata; Y Hayashi; H Stern; H Marks; M R Glasberg; J E Carroll; J W Taber; H B Wessel
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

Review 8.  Molecular and genetic basis of X-linked immunodeficiency disorders.

Authors:  J M Puck
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

9.  Wiskott-Aldrich syndrome carrier detection with the hypervariable marker M27 beta.

Authors:  G de Saint Basile; L D Notarangelo; C Bonaiti-Pellié; M Doussau; O Prolini; I W Craig; A Ugazio; C Griscelli; A Fischer
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

Review 10.  Molecular detection of altered X-inactivation patterns in the diagnosis of genetic disease.

Authors:  S Malcolm
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.